Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment
نویسنده
چکیده
Monitoring renal function and adjusting dosing for patients with impaired renal function are not required with denosumab (60 mg every 6 months). However, these patients have an increased risk for developing hypocalcemia. This case report describes a patient with renal impairment who developed severe hypocalcemia after receiving denosumab.
منابع مشابه
Severe Refractory Hypocalcemia in a Patient with Metastatic Prostate Carcinoma Following Denosumab Injection
An 86-year-old male with a history of metastatic castrate sensitive prostate cancer received a single dose of Denosumab for his bony metastases. Two weeks later, he presented to the hospital due to left foot cellulitis and was incidentally found to have profound hypocalcemia whereas his serum calcium was normal at the time of Denosumab injection. A thorough workup was undertaken which showed se...
متن کاملSevere Hypocalcemia due to Denosumab in Metastatic Prostate Cancer
Denosumab is a monoclonal antibody used for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Hypocalcemia is a rare and dangerous side effect of the drug Denosumab. We present a case of a patient with metastatic prostate cancer who developed severe hypocalcemia after the administration of the drug. The patient's vitamin D levels were low when chec...
متن کاملProlonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy
Hypocalcemia is a significant adverse effect of denosumab. We herein report a case of prolonged hypocalcemia in a patient with multiple risk factors for hypocalcemia, including gastrectomy, increased bone turnover, and a poor performance status. Hypocalcemia developed after denosumab treatment for diffuse bone metastasis of gastric cancer, despite oral supplementation with vitamin D and calcium...
متن کاملDenosumab (prolia) for treatment of postmenopausal osteoporosis.
Data on the long-term safety of denosumab are limited; the largest clinical trial enrolled approximately 7,800 women and followed them for three years.2 The most serious safety issue is the risk of hypocalcemia, which occurs in about 2 percent of women who receive Prolia.1 The risk is higher in patients with renal impairment. Denosumab is contraindicated in patients with preexisting hypocalcemi...
متن کاملSudden Bilateral Sensorineural Hearing Loss Following Postpartum Hemorrhage: A Case Report
AbstractThe prevalence of bilateral sudden sensorineural hearing loss (SSNHL) is less than 5% and the etiology of most cases is unknown. Due to many structural and functional similarities between the kidney and inner ear, many conditions, diseases, and drugs have both renal and cochlear effects and toxicities. There are several reports of SSNHL in patients with CRF, uraemic patient, hemodialysi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 1 شماره
صفحات -
تاریخ انتشار 2012